

11-03-00 A

Please type a plus (+) sign in inside this box → ☐

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new non-provisional applications under 37 CFR 1.53(b))</i>		<i>Attorney Docket No.</i> PH-7032
		<i>Beck et al.</i>
		<i>Express Mail Label No.</i> EL502309751US
		<i>Express Mailing Date</i> November 2, 2000

11/02/00

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent applications contents.		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
<p>1. <input checked="" type="checkbox"/> Fee (Authority to charge deposit account below.) <i>(Submit an original, and duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages 73] <i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none">- Descriptive title of the invention- Cross Reference to Related Application (if needed)- Statement Regarding Fed sponsored R&D (if needed)- Reference to Microfiche Appendix (if needed)- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claims: 49 [Total Pages 10]- Abstract of the Disclosure <p>3. <input type="checkbox"/> Drawing(s) (35 USC 113 [Total Pages <input type="checkbox"/>]</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages 1]</p> <ul style="list-style-type: none">a. <input type="checkbox"/> Newly executed (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d) <i>(for continuation/divisional with Box 14 completed)</i>i. <input type="checkbox"/> DELETION OF INVENTORS Signed Statement below at Box 15 deleting inventor(s) named in the prior application; see 37 CFR 1.63(d)(2) and 1.33(b). <p>5. <input type="checkbox"/> Incorporation by Reference (useable if Box 4b is checked). The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>		<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submissions <i>(if applicable, all necessary)</i></p> <ul style="list-style-type: none">a. <input type="checkbox"/> Computer Readable Copyb. <input type="checkbox"/> Paper Copy (identical to computer copy)c. <input type="checkbox"/> Statement verifying identity of above copies	
		ACCOMPANYING APPLICATION PARTS	
		<p>8. <input type="checkbox"/> Power of Attorney</p> <p>9. <input type="checkbox"/> Information Disclosure Statement (IDS) Cover Letter plus PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>10. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>12. <input type="checkbox"/> Certified Copy priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>13. <input type="checkbox"/> Other</p>	
<p>14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No.:</p>			
<p>15. <input type="checkbox"/> DELETION OF INVENTOR(S) STATEMENT: This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.63(d)(2) and 1.33(b), the Assistant Commissioner is requested to delete the name(s) of the following person or persons who are not inventors of the invention being claimed in this application:</p>			
<p>16. <input type="checkbox"/> AMEND THE SPECIFICATION BY INSERTING BEFORE THE FIRST LINE THE SENTENCE:</p> <p>-- This Application claims the benefit of U.S. Provisional Application No. 60/163,270, filed November 3, 1999. --</p>			
<p>17. <input type="checkbox"/> Cancel in this application original claims ___ of the prior application before calculating the filing fee. (At least one original independent claim is retained for filing purposes.)</p>			

Attorney Docket No.: PH-7032

Express Mailing Label No.: EL502309751US

18. Priority of foreign Application No. _____ filed on _____ in _____
 _____ is claimed under 35 U.S.C. 119.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CRR 1.16(c))		49- (20) =	29	x \$ (18) =	\$522.00
INDEPENDENT CLAIMS (37 CFR 1.16(b))		1- (3) =	0	x \$ (78) =	0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				= \$270 =	0
				BASIC FEE (37 CFR 1.16(a))	\$710.00
				TOTAL =	\$1,232.00

19. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:

a. ☒ Fees required under 37 CFR 1.16.


b. ☐ Fees required under 37 CFR 1.17

20. ☐ Other:

21. CORRESPONDENCE ADDRESS

NAME	Peter L. Dolan				
ADDRESS	DuPont Pharmaceuticals Company				
	c/o E.I. duPont de Nemours and Company				
	Legal-Patents				
	1007 Market Street				
CITY	Wilmington	STATE	Delaware	ZIP CODE	19898
COUNTRY	U.S.A.	TELEPHONE	302-992-4528	FAX	302-992-3999

22. SIGNATURE OF ATTORNEY OR AGENT REQUIRED

NAME	Peter L. Dolan	REG. NO.: 46,307
SIGNATURE		
DATE	November 2, 2000	

09704306-110200